Fermenta Biotech Ltd

Fermenta Biotech Ltd has announced the closure of its trading window from July 01, 2026, until 48 hours after the announcement of its unaudited financial results for the quarter ending June 30, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. During this period, directors, promoters, insiders, and designated persons, including auditors, are prohibited from trading in the company's securities. The specific date of the board meeting to approve the financial results will be announced in due course. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Fermenta Biotech Limited has been recognized as the 7th best mid-size workplace in India for 2026 by Great Place To Work®. This accolade highlights the company's strong people-first culture and high-trust environment, achieved during its 75th anniversary year. The ranking is based on employee feedback and a rigorous assessment of workplace culture, with over 2,000 organizations participating. This recognition follows a previous award for being among India's Best Workplaces in Pharmaceuticals, Healthcare, and Biotech 2025, underscoring Fermenta's commitment to employee value and empowerment. Managing Director Prashant Nagre attributed the success to the dedication of the team and the support of partners, emphasizing the company's legacy of trust, science, and service.

Fermenta Biotech Ltd has submitted an application to the National Stock Exchange of India Limited (NSE) seeking approval for the listing and trading of its equity shares on the NSE platform. This application follows a previous intimation filed on May 26, 2026, and utilizes a direct listing route. The company aims to expand its accessibility to investors by being listed on the NSE.

Fermenta Biotech Ltd's board recommended a final equity dividend of ₹3.75 per share (75%) for the financial year ended March 31, 2026, subject to shareholder approval at the AGM on August 11, 2026. If approved, the dividend will be paid on or before August 21, 2026. The record date for the dividend is August 5, 2026. The board also approved the audited financial results for FY26 at its meeting on May 26, 2026.

Fermenta Biotech Ltd's board approved the re-appointment of Ms. Rajeshwari Datla as a Non-Executive Director, subject to member approval. The Compensation Committee approved granting 3,95,400 stock options under the FBL ESOP 2025 at an exercise price of ₹83.67 per option. The board also approved applying to the National Stock Exchange of India Limited for direct listing and trading of equity shares. Additionally, in-principle approval was granted to Fermenta Environment Solutions Private Limited (FESPL) for a private placement of equity shares and an employee stock option plan.

Fermenta Biotech Ltd announced its FY26 audited financial results, reporting a consolidated revenue of ₹547.8 crore, up 14% YoY. Excluding real estate, revenue stood at ₹538.4 crore, a 26% increase YoY. EBITDA (excluding real estate) rose by 44% YoY to ₹120 crore, driven by strong growth in Vitamin D3 - Human Nutrition. Profit after Tax was ₹70.3 crore, down 8% YoY, impacted by a high base in FY25 due to one-time real estate inflows. The company's German toll manufacturing subsidiary's revenue increased by 101% YoY.

Fermenta Biotech Ltd's board approved the audited financial results for the quarter and year ended March 31, 2026. They recommended a final equity dividend of ₹3.75 per share (75%) for FY26, subject to member approval at the AGM. The 74th AGM will be held on August 11, 2026, via video conferencing. The record date for the dividend is August 5, 2026, and payment will be made on or before August 21, 2026.

Fermenta Biotech Ltd's board approved the audited financial results for the quarter and year ended March 31, 2026. They recommended a final equity dividend of ₹3.75 per share (75%) for FY26, subject to member approval at the AGM. The 74th AGM will be held on August 11, 2026, via video conferencing. The record date for the dividend is August 5, 2026, and payment will be made on or before August 21, 2026.

Fermenta Biotech Ltd has scheduled a Board of Directors meeting on May 26, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider and recommend the final equity dividend, if any, for the financial year 2025-26. The trading window has been closed from April 1, 2026, and will remain closed until 48 hours after the declaration of the audited financial results.

Fermenta Biotech Ltd's equity shares have been admitted for dealings under the "Permitted to Trade" category on the National Stock Exchange (Capital Market segment). This admission is effective from April 20, 2026, as per NSE Circular Ref. No. 0645/2026 dated April 17, 2026, and in pursuance of Regulation 3.1.1 of the NSE (Capital Market) Trading Regulations Part A. This development allows the company's shares to be traded on the NSE platform, expanding trading avenues for investors.